Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and CalciMedica (CALC)

CalciMedica Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate

CalciMedica Q2 FY26 Net Loss Widens to $7.65 Million

CalciMedica Q2 Basic EPS USD -0.45

Press Release: CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Inc Expected to Post a Loss of 28 Cents a Share - Earnings Preview

CalciMedica announces FDA alignment on Phase 2b Auxora trial design

CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright

CalciMedica Reaches FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis

CalciMedica - Expects Ind Submission for Cm5480 in Mid-2027

CalciMedica Announces FDA Alignment on Phase 2B Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

CalciMedica - Plans Phase 1B Trial for Auxora in Pah with Data Expected Mid-2027

CalciMedica Inc: Continues to Advance Preparations for Phase 2B Trial

CalciMedica - FDA Aligns on Phase 2B Primary Endpoint of New-Onset Severe Respiratory Failure

Calcimedica - Prospectus Covers Resale of up to 56,020,287 Shares of Common Stock - SEC Filing

Calcimedica Announces Annual Shareholder Meeting

Calcimedica Files Initial Beneficial Ownership Statement for Alafi Capital Co LLC

Calcimedica Files Form 3 Initial Beneficial Ownership Statement for Director Evgeny Zaytsev

CalciMedica Announces Board Expansion and Leadership Transition